Company Overview

Haleon plc, founded in 1715 and headquartered in Weybridge, United Kingdom, is one of the largest consumer healthcare companies in the world. The company, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products across North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company was formerly known as DRVW 2022 plc and changed its name to Haleon plc in February 2022.

Business Segments and Product Portfolio

Haleon's product portfolio spans six major categories, with a strong emphasis on global power brands.

Oral Health Products

Oral health products represent 29.5% of net sales and hold the number 1 position worldwide. Key brands include:

- Sensodyne

- Polident

- Parodontax

- Aquafresh

- Biotene

Pain Relief Medicines

Pain relief medicines account for 22.8% of sales with the number 1 global position. Key brands include:

- Panadol

- Advil

- Voltaren

- Excedrin

Vitamins, Minerals and Supplements (VMS)

VMS products contribute 15.1% of sales with global leadership. Key brands include:

- Centrum

- Emergen-C

- Caltrate

Respiratory Health

Respiratory medicines represent 14.9% of sales with worldwide leadership. Key brands include:

- Theraflu

- Otrivin

- Flonase

- Contac

Digestive Health

Digestive health medicines account for 17.7% of sales with a global number 1 position. Key brands include:

- TUMS

- Nicorette

- ENO

- Chap Stick

- Fenistil

- Nexium

The firm generates 60% of sales from its nine global power brands (including Sensodyne, Advil, Centrum, and Poligrip), which play in many geographies and are often leaders in their respective categories. It also has strong local brands, such as Emergen-C, Eno, Tums, and Caltrate, that are more tailored to regional needs and have strong local brand equity.

Financial Performance and Market Position

Haleon has demonstrated consistent financial performance, driven by strong brand equity and market leadership.

Key Financial Metrics

- Market Capitalization: $41.3B (as of September 16, 2025)

- Shares Outstanding: 8.94 billion

- Trailing Twelve Months (TTM) Revenue (as of June 30, 2025): $14.2B

- TTM Earnings Per Share (as of June 30, 2025): $0.22

- 2024 Full Year Organic Revenue Growth: 5.0%

- 2024 Full Year Organic Profit Growth: 9.8%

- 2024 Total Dividend: 6.6p per ordinary share

- 2024 Free Cash Flow: £1.9bn

Market Share and Brand Strength

Importantly, 71% of Haleon's business gained or maintained market share in 2024, demonstrating the strength and appeal of its brands with consumers worldwide. The nine Power Brands saw a 6.3% growth in 2024, contributing around three-quarters of the Group's overall growth.

Geographic Presence

Net sales are distributed geographically as follows:

- Europe/Middle East/Africa/Latin America: 41.2%

- North America: 36%

- Asia/Pacific: 22.8%

Innovation and Product Development

The company continues to drive growth through innovation across its key categories. Recent innovations include:

- Sensodyne Clinical White: The #1 innovation in the US Oral Health market, now available in over 10 markets.

- Panadol Dual Action: A new combination of ibuprofen and paracetamol.

Strategic Focus and Future Outlook

Over recent years, Haleon has achieved a more rationalized operation by divesting multiple non-strategic brands, slimming down its manufacturing footprint, and reducing the number of warehouses and distribution centers. The company has reduced SKUs by circa 16% since the beginning of 2024, putting it on track to achieve its goal of reducing SKUs by 30% over the next few years.

The company is well established to enjoy long-term industry trends, including an aging population, premiumization of consumer healthcare products, and growing emerging markets, that should fuel its top line. With financial and operational independence, Haleon expects to bolster its portfolio through product innovation and tuck-in acquisitions, and expand the strong foothold it has in the consumer self-care industry.

Haleon represents a compelling investment opportunity in the consumer healthcare sector, backed by strong brand recognition, global market leadership positions, and consistent financial performance driven by innovation and operational excellence.